Biopharma

Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'

Biopharma Recent News

Weight-Loss Drug Wegovy Adds Mass To Novo Nordisk's stock, Pushing Valuation Past Denmark's GDP
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
Cash-strapped Viva Biotech Sells Stake And Plans Spinoff
Key Takeaways： As well as tapping strategic investors, Viva Biotech is planning to list its drug research subsidiary on a Chinese exchange by the end of 2026 A sinking share price has piled pressure on the company to buy back its convertible bonds, hence the need for funds By Molly Wen
Tesla, Amazon, Ambrx, BridgeBio, Azul: Why These 5 Stocks Are Drawing Investors' Attention Today
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like Apple Inc.
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Tesla, Apple, Anavex, Axsome, Pinduoduo: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1% lower on Monday after protests in China against COVID-zero policies led to supply chain concerns.
Cathie Wood Loads Up Over $6.7M In Adobe Stock As It Tumbles 27% In A Month Over Figma Deal
Cathie Wood-led ARK Investment Management bought over 23,000 shares of software maker Adobe Inc (NASDAQ: ADBE) through the
Why Veru May Be Set To Double, Triple In Price And How To Play This Consolidation Pattern
Veru Inc (NASDAQ: VERU) shot up 235% at one point on Monday before closing the trading session up more than 180% off Friday’s closing price. On Tuesday, the stock was consolidating the move higher by setting up an inside bar pattern on the daily chart.
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.
Novavax Looks Like It's Bouncing Off Support In A Pattern
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Friday as most COVID-19-related biopharma stocks dropped. The weakness was partly due to the broader market sell-off, triggered by higher bond yields and expectations of removal of monetary policy accommodation.
5 Israeli Stocks To Consider For Passover
Back in the days of the Exodus, investment opportunities in the Holy Land were limited to a pair of options. One choice was framed by draconian terms of service that were literally chiseled in stone and regulated by an often-severe oversight authority, although the return on investment was considered heavenly.
Biotech Company Opthea Aims To Raise $160M In US IPO
Opthea Limited, a biotechnology company focussed on retinal diseases, announced Sunday it is seeking an initial public offering in the United States. What Happened: The Melbourne Australia-based biopharmaceutical company will offer American Depositary Shares each of which will represent eight of the company’s ordinary shares.
Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval
Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation
A Survey Of Celgene's M&A Strategy
After A Freefall In Axovant Shares, Chardan Upgrades
Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making
ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More
10 Biotech Stocks Moving From ASH 2017
Piper Jaffray: Akorn's Stock Will Be Delisted In 2016
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
What Should Biotech Investors Do Now?
;

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved